New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
11:01 EDTTHRX, ZOLT, SA, TROX, TERHigh option volume stocks: THRX ZOLT SA TROX TER
News For THRX;ZOLT;SA;TROX;TER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
09:05 EDTTERTeradyne shares attractive again, says Pacific Crest
Subscribe for More Information
October 22, 2014
17:50 EDTTERTeradyne sees Q4 EPS 8c-14c, consensus 17c
Subscribe for More Information
17:49 EDTTERTeradyne reports Q3 EPS 44c, consensus 40c
Subscribe for More Information
15:30 EDTTERNotable companies reporting after market close
Subscribe for More Information
14:43 EDTTHRXTheravance drops after partner announces restructuring, posts abstracts
Shares of Theravance, (THRX) a biopharmaceutical company that has economic ties to GlaxoSmithKline (GSK), are lower in afternoon trading after Glaxo reported restructuring plans. Additionally, Theravance disclosed last night that GSK is scheduled to present data from Phase 3 studies at an upcoming medical conference. CHEST 2014 in Austin, Texas, to be held from October 25-30. WHAT'S NEW: Earlier today, GlaxoSmithKline announced it intends to refocus its global pharmaceuticals business and cost base following the divestment of its oncology products and the changed dynamics now faced in the U.S. respiratory market. Theravance has strategic alliances with GlaxoSmithKline in respiratory products. Also, Theravance disclosed last night that Glaxo is scheduled to present data from Phase 3 studies at CHEST 2014, which is being held from October 25-30. Umeclidinium/Vilanterol, a once-daily combination treatment comprising two bronchodilators in Theravance's ELLIPTA inhaler, and Fluticasone Furoate/Vilanterol, a once-daily combination of a LABA and inhaled corticosteroid, have been developed under a collaboration pact between Glaxo and Theravance. Abstracts of the planned oral presentations can be found in the CHEST Journal, Theravance noted in its filing. PRICE ACTION: In afternoon trading, shares of Theravance fell 10.25% to $16.73.
11:14 EDTTHRXHigh option volume stocks
Subscribe for More Information
October 17, 2014
05:25 EDTTHRXTheravance announces positive Anoro Ellipta study data published
Subscribe for More Information
October 16, 2014
08:12 EDTSASeabridge Gold reports additional drilling results at KSM Project in Canada
Seabridge Gold announced additional results from this year's drill program at its 100% owned KSM Project in northwestern British Columbia, Canada. Results from the Iron Cap Lower Zone continue to outline a major new gold-copper discovery beneath Iron Cap, one of KSM's four large porphyry deposits. Data from eight new holes and seven holes announced previously are expected to support an initial resource estimate for the Iron Cap Lower Zone scheduled for 1Q15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use